GlassScriptPhysician profile
Jose M Marcal
NPI 1538116223
$3,033.93
in general payments reported to CMS, 2019-2025
20 companies · $408 in 2025
The $408 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,608 · 2020: $419 · 2021: $114 · 2023: $118 · 2024: $367 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832 · Education: $60.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.78 |
| Education | $60.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.07 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $552.47 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $391.74 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $254.62 | 2019-2025 | Tremfya |
| Genzyme Corporation | $203.18 | 2023-2025 | |
| Gilead Sciences, INC. | $158.09 | 2019-2020 | |
| Pfizer INC. | $155.91 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $122.78 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $77.64 | 2019-2020 | |
| Shionogi INC | $71.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $64.20 | 2019-2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $48.54 | 2019-2024 | |
| Shire North American Group INC | $48.24 | 2019 | |
| Ucb, INC. | $39.84 | 2019 | |
| Madrigal Pharmaceuticals | $26.95 | 2024 | Resmetirom |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25.62 | 2019 | |
| Aimmune Therapeutics, INC. | $23.83 | 2025 | Zenpep |
| Ardelyx, INC. | $23.06 | 2023 | Ibsrela |
| Qol Medical, LLC | $22.51 | 2024 | Sucraid |
| Organon LLC | $22.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Marcal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.